tiprankstipranks
Sartorius Stedim Biotech (SDMHF)
OTHER OTC:SDMHF
US Market
SDMHF
Sartorius Stedim Biotech
RESEARCH TOOLSreports

Sartorius Stedim Biotech (SDMHF) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

SDMHF Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Sartorius
Stedim Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SDMHF Stock 12 Month Forecast

Average Price Target

$271.11
▲(37.62% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is $271.11 with a high forecast of $303.00 and a low forecast of $242.86. The average price target represents a 37.62% change from the last price of $197.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"196":"$196","303":"$303","222.75":"$222.8","249.5":"$249.5","276.25":"$276.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":302.99514,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$303.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":271.1112621,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$271.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":242.8587,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$242.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[196,222.75,249.5,276.25,303],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.365,216.56731846153846,223.76963692307692,230.9719553846154,238.17427384615385,245.3765923076923,252.57891076923076,259.7812292307692,266.9835476923077,274.1858661538462,281.3881846153846,288.5905030769231,295.7928215384615,{"y":302.99514,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.365,214.11471246923077,218.86442493846155,223.6141374076923,228.36384987692307,233.11356234615386,237.8632748153846,242.61298728461537,247.36269975384613,252.11241222307692,256.8621246923077,261.61183716153846,266.3615496307692,{"y":271.1112621,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.365,211.94143846153847,214.51787692307693,217.09431538461538,219.67075384615384,222.2471923076923,224.82363076923076,227.40006923076925,229.9765076923077,232.55294615384616,235.12938461538462,237.70582307692308,240.28226153846154,{"y":242.8587,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":204.332,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.753,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.786,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.561,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.492,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.356,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.124,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.007,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.022,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.477,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.365,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$303.00Average Price Target$271.11Lowest Price Target$242.86
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on SDMHF
James Quigley
Goldman Sachs
Goldman Sachs
$271.77→$247.48
Buy
25.63%
Upside
Upgraded
03/30/26
Sartorius Stedim Biotech (0RG8) was upgraded to a Buy Rating at Goldman Sachs
J.P. Morgan Analyst forecast on SDMHF
Richard Vosser
J.P. Morgan
J.P. Morgan
$300.68
Buy
52.63%
Upside
Reiterated
03/18/26
J.P. Morgan Sticks to Their Buy Rating for Sartorius Stedim Biotech (0RG8)
Kepler Capital Analyst forecast on SDMHF
Oliver Reinberg
Kepler Capital
Kepler Capital
―
Buy
―
Upgraded
03/18/26
Sartorius Stedim upgraded to Buy from Hold at Kepler CheuvreuxSartorius Stedim upgraded to Buy from Hold at Kepler Cheuvreux
Barclays Analyst forecast on SDMHF
Charles Pitman CFA
Barclays
Barclays
$265.99
Buy
35.02%
Upside
Reiterated
03/17/26
Barclays Remains a Buy on Sartorius Stedim Biotech (0RG8)
Jefferies Analyst forecast on SDMHF
James Vane
Jefferies
Jefferies
$296.06→$303
Buy
53.80%
Upside
Reiterated
03/17/26
Jefferies Keeps Their Buy Rating on Sartorius Stedim Biotech (0RG8)
RBC Capital Analyst forecast on SDMHF
Charles Weston
RBC Capital
RBC Capital
$242.86
Buy
23.28%
Upside
Reiterated
03/17/26
Sartorius Stedim Biotech (0RG8) Receives a Buy from RBC Capital
Bernstein Analyst forecast on SDMHF
Susannah Ludwig
Bernstein
Bernstein
$283.34
Buy
43.82%
Upside
Reiterated
03/16/26
Sartorius Stedim Biotech (0RG8) Gets a Buy from Bernstein
UBS Analyst forecast on SDMHF
Matthew Weston
UBS
UBS
$254.42
Hold
29.15%
Upside
Reiterated
02/02/26
UBS Keeps Their Hold Rating on Sartorius Stedim Biotech (0RG8)
Exane BNP Paribas Analyst forecast on SDMHF
Odysseas Manesiotis
Exane BNP Paribas
Exane BNP Paribas
$269.46
Buy
36.78%
Upside
Initiated
05/29/25
Sartorius Stedim Biotech (0RG8) Receives a New Rating from Exane BNP Paribas
Morgan Stanley Analyst forecast on SDMHF
Thibault Boutherin
Morgan Stanley
Morgan Stanley
$300.68→$289.12
Buy
46.76%
Upside
Reiterated
04/22/25
Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR250 at Morgan StanleyMorgan Stanley analyst Thibault Boutherin lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR250.00 (from EUR260.00) while maintaining a Overweight rating.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on SDMHF
James Quigley
Goldman Sachs
Goldman Sachs
$271.77→$247.48
Buy
25.63%
Upside
Upgraded
03/30/26
Sartorius Stedim Biotech (0RG8) was upgraded to a Buy Rating at Goldman Sachs
J.P. Morgan Analyst forecast on SDMHF
Richard Vosser
J.P. Morgan
J.P. Morgan
$300.68
Buy
52.63%
Upside
Reiterated
03/18/26
J.P. Morgan Sticks to Their Buy Rating for Sartorius Stedim Biotech (0RG8)
Kepler Capital Analyst forecast on SDMHF
Oliver Reinberg
Kepler Capital
Kepler Capital
―
Buy
―
Upgraded
03/18/26
Sartorius Stedim upgraded to Buy from Hold at Kepler CheuvreuxSartorius Stedim upgraded to Buy from Hold at Kepler Cheuvreux
Barclays Analyst forecast on SDMHF
Charles Pitman CFA
Barclays
Barclays
$265.99
Buy
35.02%
Upside
Reiterated
03/17/26
Barclays Remains a Buy on Sartorius Stedim Biotech (0RG8)
Jefferies Analyst forecast on SDMHF
James Vane
Jefferies
Jefferies
$296.06→$303
Buy
53.80%
Upside
Reiterated
03/17/26
Jefferies Keeps Their Buy Rating on Sartorius Stedim Biotech (0RG8)
RBC Capital Analyst forecast on SDMHF
Charles Weston
RBC Capital
RBC Capital
$242.86
Buy
23.28%
Upside
Reiterated
03/17/26
Sartorius Stedim Biotech (0RG8) Receives a Buy from RBC Capital
Bernstein Analyst forecast on SDMHF
Susannah Ludwig
Bernstein
Bernstein
$283.34
Buy
43.82%
Upside
Reiterated
03/16/26
Sartorius Stedim Biotech (0RG8) Gets a Buy from Bernstein
UBS Analyst forecast on SDMHF
Matthew Weston
UBS
UBS
$254.42
Hold
29.15%
Upside
Reiterated
02/02/26
UBS Keeps Their Hold Rating on Sartorius Stedim Biotech (0RG8)
Exane BNP Paribas Analyst forecast on SDMHF
Odysseas Manesiotis
Exane BNP Paribas
Exane BNP Paribas
$269.46
Buy
36.78%
Upside
Initiated
05/29/25
Sartorius Stedim Biotech (0RG8) Receives a New Rating from Exane BNP Paribas
Morgan Stanley Analyst forecast on SDMHF
Thibault Boutherin
Morgan Stanley
Morgan Stanley
$300.68→$289.12
Buy
46.76%
Upside
Reiterated
04/22/25
Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR250 at Morgan StanleyMorgan Stanley analyst Thibault Boutherin lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR250.00 (from EUR260.00) while maintaining a Overweight rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sartorius Stedim Biotech

3 Months
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+2.10%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +2.10% per trade.
1 Year
Charles WestonRBC Capital
Success Rate
7/9 ratings generated profit
78%
Average Return
+6.69%
Copying Charles Weston's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +6.69% per trade.
2 Years
xxx
Success Rate
7/9 ratings generated profit
78%
Average Return
+6.69%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +6.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SDMHF Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
0
0
0
0
2
Buy
7
10
5
6
9
Hold
2
2
2
5
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
12
7
11
18
In the current month, SDMHF has received 11 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. SDMHF average Analyst price target in the past 3 months is 271.11.
Each month's total comprises the sum of three months' worth of ratings.

SDMHF Financial Forecast

SDMHF Earnings Forecast

Next quarter’s earnings estimate for SDMHF is $1.42 with a range of $1.38 to $1.53. The previous quarter’s EPS was $1.29. SDMHF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SDMHF has Performed in-line its overall industry.
Next quarter’s earnings estimate for SDMHF is $1.42 with a range of $1.38 to $1.53. The previous quarter’s EPS was $1.29. SDMHF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SDMHF has Performed in-line its overall industry.

SDMHF Sales Forecast

Next quarter’s sales forecast for SDMHF is $875.35M with a range of $866.38M to $881.06M. The previous quarter’s sales results were $892.85M. SDMHF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SDMHF has Performed in-line its overall industry.
Next quarter’s sales forecast for SDMHF is $875.35M with a range of $866.38M to $881.06M. The previous quarter’s sales results were $892.85M. SDMHF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SDMHF has Performed in-line its overall industry.

SDMHF Stock Forecast FAQ

What is SDMHF’s average 12-month price target, according to analysts?
Based on analyst ratings, Sartorius Stedim Biotech’s 12-month average price target is 271.11.
    What is SDMHF’s upside potential, based on the analysts’ average price target?
    Sartorius Stedim Biotech has 37.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SDMHF a Buy, Sell or Hold?
          Sartorius Stedim Biotech has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Sartorius Stedim Biotech’s price target?
            The average price target for Sartorius Stedim Biotech is 271.11. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $303.00 ,the lowest forecast is $242.86. The average price target represents 37.62% Increase from the current price of $197.
              What do analysts say about Sartorius Stedim Biotech?
              Sartorius Stedim Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of SDMHF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.